LUND, Sweden, Dec. 20, 2013 (GLOBE NEWSWIRE) -- Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that its collaboration partner Teva Pharmaceutical Industries has been notified that The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has not reached a final decision for laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS). It is anticipated that the CHMP will issue an opinion at its January, 2014 meeting.
For further information, please contact:
Tomas Leanderson
Phone: +46 (0)46 19 20 95
E-mail: tomas.leanderson@activebiotech.com
Hans Kolam
Phone: +46 (0)46 19 20 44
E-mail: hans.kolam@activebiotech.com
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. In pivotal phase is laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis. Also tasquinimod for the treatment of prostate cancer, with a unique mode of action, is in pivotal phase. In addition, laquinimod has concluded Phase II development for Crohn's and Lupus. The company has two additional projects in clinical development, ANYARA primarily for the treatment of renal cell cancer and the orally administered compound paquinimod (57-57) for systemic sclerosis. Please visit www.activebiotech.com for more information.
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication 1:10 p .m. CET on December 20, 2013.
Laquinimod CHMP/EMA Opinion http://hugin.info/1002/R/1751563/590490.pdf
HUG#1751563